anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients randomized to the decision aid arm will receive all of the above as well as a shared decision making aid. This will be a 10-minute tablet- or web-based intervention administered by one of our wraparound care service team members in-person or via telehealth (or possibly in person depending on pandemic procedures). IT will be a 10-minute procedure with summary of decision considerations and patient value assessment.The provider will have access to then have access to this summary in making final care decisions with the patient.
Participants with 1 liver or lung metastasis - Treatment Group 5: Ipilimumab 3 mg/kg by vein on Day 1 of Cycle 1. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 2 - 4. Each cycle is 21 days. SBRT 60 Gy in 10 fractions to 1 - 4 lung, liver, or adrenal lesion (s) on Days 1 - 5 and Days 9 - 12 of Cycle 1.
This consensus document analyzed the management and emotional journey of patients with GPP (generalized pustular psoriasis), and the desirable course of the disease while detecting critical points and translating them into needs and recommendations. This project was conducted in 3 phases with participation from an advisory committee (n=8), an expert panel (n=15) and patients with GPP (n=6). The patients' disease progression was heterogeneous due to disease variations, different health care models implemented and available resources, and the lack of diagnostic and treatment guidelines. A total of 45 different recommendations have been made to optimize management and address the emotional component of these patients. Five of them stand out for their impact and viability. Therefore, a roadmap of priorities has been made generally available to improve the management of patients with GPP.
The primary objective of the study is to dissect the bacteria contribution to valve calcification. The Authors hypothesized that a subclinical or latent valvular bacterial infiltration facilitates a chronic inflammation and contributes to accelerated structural valve degeneration. The Authors expect to find a correlation between bacterial detection (as qualitative -positive/negative, quantitative -quantitative PCR) and bone calcification markers on valves. To dissect the bacteria contribution to valve calcification, the osteogenic differentiation capabilities of primary cells obtained from cusp explanted from control and from non-calcified cusp of CAVD patients will be assessed in vitro in absence and in presence of bacterial infection. There are currently no data in the literature that can be referred to for the calculation of the sample size. Cusp calcifications do not equally affect all cusps, considering calcified cusp as cases and non-calcified cusp of the same valve as matched controls, if the probability of bacterial detection among sampled control non calcified cusps is 10% (Cohen, doi: 10.1016/S0003-4975(03)01454-1), a sample of 32 patients (with 32 calcified cusp and 96cusps) can be enrolled. This sample of 96 cusps achieves 81% power to detect an odds ratio of 5.00 versus the alternative of equal odds using a McNemar test with a 0.05 significance level. This calculation is done considering that the probability of bacterial detection in each cusp is almost independent from other cusps of the same valve (intra-valve correlation coefficient= 0.10). The Authors expect a total study duration of 24 months. The Authors estimate to complete recruitment in 12 months. The estimated primary completion is month 15 (3 months after last subject enrollment) and study completion on month 24 (12 months after last patient inclusion)
The sham (cathodal) electrode will be placed over the left supraorbital ridge. The current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session.
1. Ibalizumab is a humanized immunoglobulin G monoclonal antibody directed against a human T-cell receptor (CD4) and thus suppresses HIV replication by blocking entry of HIV into CD4+ lymphocytes. Ibalizumab is in the pipeline for FDA approval to treat HIV infection. Phase I and II clinical studies have been completed in HIV-negative and HIV-infected individuals showing safety and efficacy for suppressing HIV replication.
2. Use of this medication requires that a single patient IND be obtained from the FDA for each patient requiring ibalizumab. An individual use IND has been approved by the FDA for one patient on treatment through this protocol; The IND number is 114515. The manufacturer of ibalizumab (TaiMed Biologics, Inc) will ship the drug directly to the Denver Health pharmacy.
Patients with Akt mutation receive capivasertib PO BID on days 1-4, 8-11, 15-18, and 22-25. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. The present invention also relates to the use of the microporous zirconium silicate compositions in the treatment of diseases, where the subject is not concurrently receiving lithium based drugs. Also disclosed is a method for preparing high purity crystals of ZS-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
NEW MATERIAL:An addition compound of a thiamine disulfide shown by the formula (n is 10-16) and 12-18C higher fatty acid in a molar ratio of 1:6. EXAMPLE:A thiamine disulfide-octadecanoic acid addition compound in a molar ratio of 1:6. USE:Useful for pharmaceutical manufacturing for vitamin B1-containing pharmacuetical preparation, having more reduced bitterness than thiamine disulfide, easily taken internally even in the dosage form of powder, granule, fine granule, etc. Having higher critical humidity than thiamine disulfide in storage under high temperature and high humidity, having improved shelf stability. PREPARATION:1mol thiamine disulfide is reacted with 6mol 12-18C higher fatty acid in a solvent such as 1,2-dichloroethane, etc. at 30-90 deg.C to give an addition compound shown by the formula.
BACKGROUND: Washing red blood cell (RBC) units mitigates severe allergic transfusion reactions. However, washing reduces the time to expiration and the effective dose. Automated washing is time- and labor-intensive. A shortage of cell processor tubing sets prompted review of medical necessity for washed RBC for patients previously thought to require washing.
STUDY DESIGN AND METHODS: A single-center, retrospective study investigated discontinuing wash RBC protocols in chronically transfused adults. In select patients with prior requirements for washing, due to a history of allergic transfusion reactions, trials of unwashed transfusions were performed. Patient demographic, clinical, laboratory, and transfusion data were compiled. The per-unit washing cost was the sum of the tubing set, saline, and technical labor costs.
RESULTS: Fifteen patients (median age 34 years interquartile range [IQR] 23-53 years, 46.7% female) were evaluated. These patients had been transfused with a median of 531 washed RBC units (IQR 244-1066) per patient over 12 years (IQR 5-18 years), most commonly for recurrent, non-severe allergic reactions. There were no transfusion reactions with unwashed RBCs aside from one patient with one episode of pruritus and another with recurrent pruritus, which was typical even with washed RBC. We decreased the mean number of washed RBC units per month by 72.9% (104 ± 10 vs. 28.2 ± 25.2; p < .0001) and saved US $100.25 per RBC unit.
CONCLUSION: Washing of RBCs may be safely reconsidered in chronically transfused patients without a history of anaphylaxis. Washing should be implemented judiciously due to potential lack of necessity and logistical/operational challenges.
This randomized prospective study was designed to compare the clinical, functional and aesthetic results of two surgical techniques for microsurgical clipping of anterior circulation aneurysms. Overall, 60 eligible patients admitted with ruptured and unruptured anterior circulation aneurysms will enrolled in the study.

The aesthetic results will be analyzed with 2 methods. In the first, the patients will be showed to a rule, with a scale from 0 to 100, in which 0 mean the best result and 100 the worst result. Photos will be taken and showed to two independent observers, the results will be classified as excellent, good, regular or poor. The degree of atrophy will be measured with three methods. In the first one, the authors wiil observes the percentage of thick reduction in the temporal muscle, subcutaneous tissue and skin. In the second method the percentage thick reduction of the isolated temporal muscle will be measured and the third the volumetric analysis of the temporal muscle, subcutaneous tissue and skin will be calculated from the superior edge of zygomatic arch to superior temporal line. The functional results wiil be compared using the Modified Rankin Score. Others variables such frontal facial palsy, post-operative hemorrhage, cerebrospinal fistulas, hydrocephalus and mortality will be also analyzed
Subjects with a diagnosis of SCZ will complete aerobic exercises consisting of spin classes 3 times a week on a stationary bicycle ergometer. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
Three consecutive doses of 100cc IV normal saline (0.9%), will be administered over three days. Each dose will be administered over 24 hours in a slow drip.
Disclosed herein are system, method, and computer program product embodiments for linking a point of care (POC) testing media and a test result form using image analysis. In some embodiments, a server receives an image of a diagnostic test result form and a POC diagnostic testing media. The server confirms that the diagnostic test result form and the POC diagnostic testing media are positioned in a predetermined position such that the patient's information and the patient identifier are visible in the image. Furthermore, the server verifies that the diagnostic test result form and the POC diagnostic testing media correspond to the patient. The server extracts the form ID and one or more values on the diagnostic test result form from the image. The server transmits the patient information, the patient identifier, the form ID, and the one or more values to a client device.
The Silva pattern-based classification of HPV-associated endocervical adenocarcinoma has become an integral part of the histologic assessment of these tumors. Unfortunately, the Silva system reproducibility has had mixed results in past studies, and clinical practice still favors the FIGO stage assessment in directing therapeutic interventions for patients. In our study, we aimed to assess our institution's concordance including not only gynecologic pathologists, but also pathology trainees through a series of 69 cases. The grouped total kappa concordance from all participants was 0.439 (Moderate), with an overall trainee kappa of 0.417 (moderate) and an overall pathologist kappa of 0.460 (moderate). Perfect concordance among all 10 study participants was seen in 8/69 cases (11.6 %), corresponding to 5/22 Pattern A cases (22.7 %), 0/16 Pattern B cases (0 %), and 3/31 Pattern C cases (9.7 %), with similar findings between trainees and pathologists when compared within their own cohorts. Recurrence was identified in 2 Pattern A cases, indicating a potential issue with limited excisional specimens which may not fully appreciate the true biologic aggressiveness of the lesions.
Electrical field-guided positioning of a second device within a body cavity, using electrical field mapping information generated from electrical field measurements by electrodes of a first device. The first device, in some embodiments, is a catheter electrode probe, and the second device is an internally implantable and/or operated medical device. An exposed, electrically conductive portion of the second device is optionally configured to be used as an electrical field measuring electrode. A rule is applied to measurements made by this electrode to estimate its position within a body cavity. The rule is generated, in some embodiments, using measurements made by the first device. In some embodiments, electrical measurements are used to guide implantation verification. In some embodiments, electrical measurements are used to guide navigation at and through a septal wall between body cavities.
Two open coil springs were inserted. The first coil spring was inserted between the maxillary second premolar and the maxillary first molar with a distalization force 300gm, and the second coil spring was inserted between the maxillary first and maxillary second molar with a distalization force 200 gm.
Current studies on salvage radiotherapy (sRT) for biochemically recurrent prostate cancer after radical prostatectomy investigate timing, dose-escalation and androgen deprivation therapy (ADT) for recurrent prostate cancer. These approaches could either be limited by radiation-related susceptibility of the anastomosis or by suspected side-effects of ADT. A phase II protocol was developed to investigate the benefit and tolerability of regional hyperthermia with moderately dose-escalated sRT. The study hypothesis is that hyperthermic sRT is a safe and feasible salvage treatment modality. The primary endpoint is safety measured by frequency of grade 3+ genitourinary (GU) and gastrointestinal (GI) adverse events (AE) according to Common Toxicity Criteria (CTC) version 4. Feasibility is defined by number of hyperthermia treatments (n ≥ 7) and feasibility of sRT according to protocol. Target volume delineation is performed according to the EORTC guidelines. sRT is administered with single doses of 2 Gy 5×/week to a total dose of 70 Gy to the prostate bed, or alternatively the total dose only to the area of highest risk and a lower dose to the remaining prostate bed using a simultaneous boost (SIB) technique. Regional hyperthermia is given 2×/week to a total of 10 treatments. German centres participate in the phase II trial using intensity modulated RT (IMRT), volumetric modulated arc technique (VMAT) or tomotherapy. The initiating centres were participants of the SAKK 09/10 study, where the same patient criteria and target volume definition (mandatory successful performed dummy run) were applied insuring a high standardisation of the study procedures.

The introduced phase II study implements modern sRT and regional hyperthermia. If the phase II study is found to be safe and feasible, a multicenter phase III study might be performed to test whether the addition of regional hyperthermia to dose-intensified sRT improves biochemical control.
OBJECTIVE: Fibroblast activation protein α (FAP) is expressed in normal adipose tissue and related to some pleiotropic metabolic regulators. However, the exact role and mechanism of FAP in obesity and related metabolic disorders are not well understood.
METHODS: FAP knockout mice were fed a normal diet or a high-fat diet (HFD) for 12 weeks. FAP knockout mice or wild-type mice treated with an FAP inhibitor were subjected to cold stress for 5 days.
RESULTS: FAP deficiency protected mice against HFD-induced obesity and obesity-associated metabolic dysfunction, including glucose intolerance, insulin resistance, hyperglycemia, hyperinsulinemia, and hyperlipidemia. Notably, FAP deficiency largely reversed obesity-induced adipose tissue macrophage accumulation and M1-M2 imbalance in white adipose tissue (WAT). Moreover, energy expenditure was significantly higher in FAP-deficient mice fed an HFD. Both FAP deficiency and inhibition increased cold tolerance through enhancing WAT beiging.
CONCLUSIONS: This study demonstrated that FAP deficiency protects mice against diet-induced obesity and related metabolic dysfunction. Furthermore, the protective effects are probably mediated via the promotion of WAT beiging and suppression of inflammation.
Antimicrobial peptides (AMPs) are crucial components of the innate immune system in various organisms, including humans. Beyond their direct antimicrobial effects, AMPs play essential roles in various physiological processes. They induce angiogenesis, promote wound healing, modulate immune responses, and serve as chemoattractants for immune cells. AMPs regulate the microbiome and combat microbial infections on the skin, lungs, and gastrointestinal tract. Produced in response to microbial signals, AMPs help maintain a balanced microbial community and provide a first line of defense against infection. In preterm infants, alterations in microbiome composition have been linked to various health outcomes, including sepsis, necrotizing enterocolitis, atopic dermatitis, and respiratory infections. Dysbiosis, or an imbalance in the microbiome, can alter AMP profiles and potentially lead to inflammation-mediated diseases such as chronic lung disease and obesity. In the following review, we summarize what is known about the vital role of AMPs as multifunctional peptides in protecting newborn infants against infections and modulating the microbiome and immune response. Understanding their roles in preterm infants and high-risk populations offers the potential for innovative approaches to disease prevention and treatment.
The invention relates to a carbazochrome sodium sulfonate compound which is a crystal. The characteristic peak in a map through X-ray powder diffraction determination is 12.5 degrees, 17.4 degrees, 19.8 degrees, 21.0 degrees, 21.5 degrees, 23.4 degrees, 26.2 degrees, 26.8 degrees, 27.7 degrees, 29.0 degrees, 3.01 degrees, 31.6 degrees, 32.1 degrees, 35.0 degrees, 38.5 degrees, 40.3 degrees and 51.9 degrees at 2theta+/-0.2 degrees. The invention further provides a medical composition preparation containing the carbazochrome sodium sulfonate compound. The medical composition preparation is a freeze-dried powder injection, a water injection and a troche. The compound provided by the invention can be prepared in various medical forms and is extremely high in stability. The carbazochrome sodium sulfonate freeze-dried powder, water injection and troche preparations provided by the invention are simple in formulation and technology, the stability is remarkably improved, and the pharmaceutical safety and effectiveness are improved.
FIELD: medicine, oncology. SUBSTANCE: invention elates to agent for fluorescent diagnosis and photodynamic therapy based on using 5-aminolevulinic acid hydrochloride as a prosensitizing agent. Agent represents 5-aminolevulinic acid hydrochloride immobilized on biosoluble polymer that comprises a mixture of hydrophilic and lipophilic modifying components and a taste supplement. Agent represents buccal plate of the following composition, wt. -%: 5- aminolevulinic acid hydrochloride, 31-55; biosoluble polymer, 35-50; lipophilic component, 3-11; hydrophilic component, 2-8; taste supplement, 3-6. As a biosoluble polymer copolymer of vinylpyrrolidone, ethyl acrylate and acrylamide is used that is characterized by ratio of the parent monomers, wt.-% = 20:20:60, respectively, and molecular mass 200 000 1 000 000 Da. As a lipophilic addition the dispersions of hydrogenated fats, menthol oil, cacao oil or their mixtures are used. As a hydrophilic addition glycerol or polyethylene oxide with molecular mass 600- 4 000 Da or their mixtures are used. As taste supplements saccharin, calcium succaryl, aspartam or their mixtures are used. Proposed agent provides transmucose transport of 5-aminilevulnic acid hydrochloride in arterial and lymphatic systems of body that promotes to its selectivity for neoplasms in significant reducing its concentration in normal tissues, effectiveness of diagnosis and PhDTh. EFFECT: enhanced effectiveness and valuable medicinal properties of agent. 5 cl, 8 ex
The present invention relates to a method for preparing medicine for treating gastritis, gastric ulcer and duodenal ulcer. The present invention adopts good Chinese herbal medicine of musk, chicken gizzard-membrane, pharbitis seed, cinnamon and human placenta and western medicine of furazolidone and vitamin B6 as raw materials. After the raw materials are cleaned, dried, parched, mixed, pulverized and sieved, the raw materials are made in oral administration capsules or medicinal powder. The present invention can be used for promoting the stomach intestine function to recover normal, and has the advantages of obvious effect, low relapse rate, high cure rate and no toxic or side effect. Through years of clinical verification, common patients can be cured by taking the medicine for about 40 days, and the cure rate reaches more than 90.5%. The present invention is the ideal medicine for treating gastropathy.
A system for predicting and detecting urination events of users is disclosed. The system can include any number of wearable devices, mobile devices, hubs, computing devices, and servers to collect, share, process, and interpret data, as well as to provide stimuli to users and caregivers. Biometric and/or environmental data associated with a user can be collected and applied to a urination model to determine a predicted urination time. The user or a caregiver can be provided with direct or environmental stimuli conveying information about predicted urination times. Ongoing biometric and/or environmental data collection can be used to identify, and provide stimuli warning of, imminent urination events. Voluntary and involuntary feedback of actual urination events, as well as continued biometric and/or environmental data collection, can be used to train individual and collective urination models.
The invention relates to an animal forage additive and relative preparation. The invention is characterized in that the additive comprises 90-99 deals of green tea, and 1-10 deals of white carbon and/or bamboo charcoal. And the preparation comprises that dewatering, twisting, baking, drying, screening, cutting, and frying the fresh tea, to prepare the green tea; putting the bamboo or nontoxic wood in the fixed furnace to be burnt at 700-1000Deg. C or 800-1300Deg. C for 23-27 days, to prepare the bamboo charcoal or white carbon; mixing the green tea with said white carbon and/or bamboo charcoal. The invention can reduce the heat, fatty, and cholesterol contents of edible animal, egg and milk, without side effect and pollution.